Popular antidepressant recalled for high levels of a potentially cancer-causing chemical

Breckenridge Pharmaceutical has issued a recall for nearly 360,000 bottles of duloxetine, a generic antidepressant, due to elevated levels of nitrosamines. The FDA-monitored action addresses concerns that these chemical compounds may increase the risk of cancer in patients. This recall is significant for the pharmaceutical sector as it underscores the ongoing challenges of maintaining purity standards in high-volume generic drug manufacturing.

Breckenridge Pharmaceutical is recalling approximately 360,000 bottles of duloxetine delayed-release capsules, which serve as a generic version of the popular antidepressant Cymbalta. The recall was officially initiated on June 4 after the FDA identified high levels of nitrosamines, a chemical compound classified as a potential carcinogen. The action impacts both 30-mg and 60-mg sizes of the medication, highlighting a major quality control issue for the manufacturer.

Specific details provided by the FDA indicate that the 30-mg capsules under recall are identified by lot code 241180C and carry an expiration date of April 2027. The scale of the recall, involving hundreds of thousands of units, reflects the broad reach of Breckenridge’s distribution network for this specific generic product. This incident adds to a series of industry-wide concerns regarding nitrosamine impurities that have prompted various regulatory actions across different therapeutic classes in recent years.

Patients who possess the recalled medication are urged to contact their doctors or pharmacists to discuss alternative treatments or next steps. Health experts emphasize that individuals should not stop taking the prescription drug without first speaking to a medical professional, as abrupt discontinuation can be dangerous. For the pharmaceutical industry, this event reinforces the necessity of rigorous testing protocols to detect and eliminate potentially harmful chemical byproducts during the production process.